Solara Active Pharma Sciences Announces Final Call for Rights Issue Shares
Solara Active Pharma Sciences approved a final call of ₹ 112.50 per equity share for partly-paid Rights Shares. The record date for this call is set for April 02, 2026. This action pertains to the Rights Issue initiated with a Letter of Offer dated May 09, 2024.
This is a routine call for payment on existing rights shares and does not represent new financial events or significant business changes.
The announcement is a procedural update regarding a rights issue, with no immediate positive or negative financial implications stated.
Solara Active Pharma Sciences Limited announced the outcome of its Rights Issue Committee meeting held on March 24, 2026. The committee approved making the Second & Final call of ₹ 112.50 per equity share for the partly-paid Rights Shares. This amount includes ₹ 3.00 towards face value and ₹ 109.50 towards securities premium, as per the Letter of Offer dated May 09, 2024.
The Rights Issue Committee has fixed Thursday, April 02, 2026, as the Record Date. This date will be used to determine the holders of partly-paid Equity Shares who will receive the call notice for payment of the final call amount. The meeting of the Rights Issue Committee commenced at 9:30 AM and concluded at 9:55 AM on March 24, 2026.
What to do with a filing like this
Solara Active Pharma Sciences Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Solara Active Pharma Sciences Limited. Read the original for the full detail.